Key result
The chimeric AAV2/2i8 vector provided sustained delta sarcoglycan expression in skeletal muscle without detectable liver targeting after 7 months, unlike the AAV2/8 vector.
Why the study?
Does a chimeric AAV2/2i8 vector reduce liver targeting and improve muscle expression compared to AAV2/8 in BIO14.6 hamsters?
Does a chimeric AAV2/2i8 vector reduce liver targeting and improve muscle expression compared to AAV2/8 in BIO14.6 hamsters?
The chimeric AAV2/2i8 vector provides a safer, liver-detargeted option for long-term gene therapy in muscular dystrophy and cardiomyopathy models.
Answers are grounded in this paper and cite their sources.
May support safer AAV vectors for muscular dystrophy gene therapy; leaves open human translation from animal models.
The BIO14.6 hamster carries a mutation in the delta sarcoglycan gene causing muscular dystrophy and cardiomyopathy. The disease can be prevented by systemic delivery of delta sarcoglycan cDNA using adeno-associated viruses (AAVs). However, all AAVs also target the liver, raising concerns about their therapeutic efficacy in human applications. We compared the AAV2/8 with the chimeric AAV2/2i8, in which the 585-QQNTAP-590 motif of the AAV8 serotype was added to the heparan sulfate receptor footprint of the AAV2 strain. Both vectors carrying the human delta sarcoglycan cDNA were delivered into 24 14-day-old BIO14.6 hamsters. We followed transgene expression in muscle and liver for 7 months. We detected a sustained ectopic expression of delta sarcoglycan in the liver when using AAV2/8 but not AAV2/2i8. Genomic copies of AAV2/2i8 were not detectable in the liver, while at least 100-fold more copies of AAV2/8 were counted. In contrast, the hamster skeletal muscle expressed more delta sarcoglycan using AAV2/2i8 and were still healthy after 7 months at the lower dosage. We conclude that this chimeric vector is a robust option for safer and longer-term diseased muscle targeting.
No takes yet. Share an insight, caveat, or question.
Rotundo et al. (2013) studied Muscular dystrophy and cardiomyopathy (BIO14.6 hamster model) (n=56). AAV2/2i8 vector vs. AAV2/8 vector was evaluated on Transgene expression in muscle and liver. The chimeric AAV2/2i8 vector provided sustained delta sarcoglycan expression in skeletal muscle without detectable liver targeting after 7 months, unlike the AAV2/8 vector.
Synapse has enriched 10 related papers. Consider them for comparative context: